My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 111

    1.

    Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.

    Greenspan SL, Oppenheim DS, Klibanski A.

    Ann Intern Med. 1989 Apr 1;110(7):526-31.PMID: 2923387 [PubMed - indexed for MEDLINE]Related articles

    2.

    Osteoporosis in men with hyperprolactinemic hypogonadism.

    Greenspan SL, Neer RM, Ridgway EC, Klibanski A.

    Ann Intern Med. 1986 Jun;104(6):777-82.PMID: 3706929 [PubMed - indexed for MEDLINE]Related articles

    3.

    Elevated serum lipids in hypogonadal men with and without hyperprolactinemia.

    Oppenheim DS, Greenspan SL, Zervas NT, Schoenfeld DA, Klibanski A.

    Ann Intern Med. 1989 Aug 15;111(4):288-92.PMID: 2757313 [PubMed - indexed for MEDLINE]Related articles

    4.

    Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study.

    Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW, Felson DT.

    Ann Intern Med. 2000 Dec 19;133(12):951-63.PMID: 11119396 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men.

    Leifke E, Körner HC, Link TM, Behre HM, Peters PE, Nieschlag E.

    Eur J Endocrinol. 1998 Jan;138(1):51-8.PMID: 9461316 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effects of prolactin and estrogen deficiency in amenorrheic bone loss.

    Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V.

    J Clin Endocrinol Metab. 1988 Jul;67(1):124-30.PMID: 3379129 [PubMed - indexed for MEDLINE]Related articles

    7.

    Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.

    Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G.

    J Clin Endocrinol Metab. 1998 Mar;83(3):807-13.PMID: 9506732 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

    Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A.

    J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65.PMID: 8954042 [PubMed - indexed for MEDLINE]Related articles

    9.

    Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism.

    Jackson JA, Kleerekoper M, Parfitt AM.

    Ann Intern Med. 1986 Oct;105(4):543-5.PMID: 3752759 [PubMed - indexed for MEDLINE]Related articles

    10.

    Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism.

    Katznelson L, Rosenthal DI, Rosol MS, Anderson EJ, Hayden DL, Schoenfeld DA, Klibanski A.

    AJR Am J Roentgenol. 1998 Feb;170(2):423-7.PMID: 9456958 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.

    Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr.

    Ann Intern Med. 1987 Mar;106(3):354-61.PMID: 3544993 [PubMed - indexed for MEDLINE]Related articles

    12.

    Increased incidence of diagnosed depressive illness in hypogonadal older men.

    Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR.

    Arch Gen Psychiatry. 2004 Feb;61(2):162-7.PMID: 14757592 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.

    Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, Crowley WF Jr.

    J Clin Endocrinol Metab. 1989 Oct;69(4):776-83.PMID: 2674186 [PubMed - indexed for MEDLINE]Related articles

    14.

    The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition.

    Howell SJ, Radford JA, Adams JE, Shalet SM.

    Clin Endocrinol (Oxf). 2000 May;52(5):609-16.PMID: 10792341 [PubMed - indexed for MEDLINE]Related articles

    15.

    Increase in bone mass after treatment of hyperprolactinemic amenorrhea.

    Klibanski A, Greenspan SL.

    N Engl J Med. 1986 Aug 28;315(9):542-6.PMID: 3736637 [PubMed - indexed for MEDLINE]Related articles

    16.

    Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?

    Diamond T, Stiel D, Posen S.

    Ann Intern Med. 1989 Mar 15;110(6):430-6.PMID: 2919850 [PubMed - indexed for MEDLINE]Related articles

    17.

    Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.

    Zacharin MR, Pua J, Kanumakala S.

    Clin Endocrinol (Oxf). 2003 Jun;58(6):691-5.PMID: 12780744 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Bone tissue in patients with hyperprolactinemic hypogonadism]

    Rozhinskaia LIa, Marova EI, Dzeranova LK, Rassokhin BM, Purtova GS, Goncharov NP, Mishchenko BP, Ilovaĭskaia IA.

    Probl Endokrinol (Mosk). 1992 Nov-Dec;38(6):17-9. Russian. PMID: 1302840 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of testosterone replacement in hypogonadal men.

    Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL.

    J Clin Endocrinol Metab. 2000 Aug;85(8):2670-7.PMID: 10946864 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Prevalence of osteopenia in men with prolactinoma.

    Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH.

    J Endocrinol Invest. 2005 Jan;28(1):12-7.PMID: 15816365 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity